Activating piezo1 and piezo2 channels for neuroprotection and axon regeneration in the retina and optic nerve

EP4746885A2Pending Publication Date: 2026-05-27THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Filing Date
2024-07-01
Publication Date
2026-05-27

AI Technical Summary

Technical Problem

Current therapies for glaucoma focus on lowering intraocular pressure (IOP) but fail to prevent blindness in up to a quarter of patients, highlighting a need for new neuroprotective strategies to prevent retinal ganglion cell loss and regenerate axon connections.

Method used

Administering an agonist of Piezo mechanosensitive ion channels, such as PIEZO1 or PIEZO2, or using a recombinant nucleic acid or expression vector expressing these channels to treat optic neuropathies and optic nerve injuries, thereby promoting retinal ganglion cell survival and axon regeneration.

Benefits of technology

The proposed method increases the survival of retinal ganglion cells and enhances axon regeneration in subjects with optic neuropathies, offering a potential neuroprotective strategy beyond traditional IOP reduction therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024036414_23012025_PF_FP_ABST
    Figure US2024036414_23012025_PF_FP_ABST
Patent Text Reader

Abstract

Methods of treating an optic neuropathy or an optic nerve injury in a subject are provided. Aspects of the methods include administering an effective amount of an agonist of a Piezo mechanosensitive ion channel, a recombinant nucleic acid or an expression vector expressing a Piezo mechanosensitive ion channel, or a Piezo mechanosensitive ion channel to the subject. Also provided are pharmaceutical formulations comprising an agonist of a Piezo mechanosensitive ion channel, a recombinant nucleic acid or an expression vector expressing a Piezo mechanosensitive ion channel, or a Piezo mechanosensitive ion channel. In some embodiments, the agonist of the Piezo mechanosensitive ion channel, the recombinant nucleic acid or expression vector expressing the Piezo mechanosensitive ion channel, or the Piezo mechanosensitive ion channel is administered to treat glaucoma, ischemic optic neuropathy, optic neuritis, or traumatic optic neuropathy.
Need to check novelty before this filing date? Find Prior Art